|
|
|
|
Vol. 61, Issue 2, 360-368, February 2002
an
Sket, and
Brain Research Laboratory, Institute of Pathophysiology, School of Medicine, University of Ljubljana, Ljubljana, Slovenia
| |
Abstract |
|---|
|
|
|---|
Parkinsonism, a common unwanted side effect of typical antipsychotic (neuroleptic) drugs, is induced by the blockade of striatal dopamine D2 receptors. In rats with hemi-parkinsonism induced by unilateral lesion of dopaminergic nigrostriatal neurons with 6-hydroxydopamine, D2 antagonists inhibit contralateral turning induced by D2 agonists and augment the levels of neurotensin mRNA in dopaminergically intact striatum. By contrast, D1 agonists induce contralateral turning and augment neurotensin mRNA levels in dopamine-depleted striatum. These effects could be inhibited by D1 but not by D2 antagonists. Here we used a hemi-parkinsonian model to investigate the effects of putative D1 agonist/D2 antagonist LEK-8829 (9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate), an experimental antipsychotic, on turning behavior and the expression of striatal neurotensin, preprotachykinin and neurotransmitter-induced early gene protein 4 (ania-4) mRNAs. We found that LEK-8829 inhibited contralateral turning induced by D2 agonist quinpirole, but only if the rats were cotreated with D1 antagonist SCH-23390. In situ hybridization showed that LEK-8829 induced the expression of neurotensin and ania-4 mRNAs in dopamine-intact striatum that could be completely blocked only by the combined treatment with SCH-23390 and quinpirole. In addition, LEK-8829 augmented the expression of neurotensin, preprotachykinin and ania-4 mRNAs in dopamine-depleted striatum that could be completely blocked by SCH-23390. This study clearly demonstrates that in hemi-parkinsonian rats D1 agonistic activity of LEK-8829 confers its anti-parkinsonian drug-like properties and modulates its neuroleptic drug-like properties, which are dependent on the blockade of dopamine D2 receptors. These findings imply that atypical antipsychotics with D1 intrinsic activity might have a reduced propensity for the induction of extrapyramidal syndrome.
| |
Introduction |
|---|
|
|
|---|
The
blockade of dopamine D2 receptors by typical antipsychotics
(neuroleptics) often provokes unwanted extrapyramidal syndrome (EPS),
characterized by parkinsonism, akathisia, catalepsy, and, after
long-term treatment, tardive dyskinesia (Deniker, 1990
). Fortunately,
atypical antipsychotic drugs, such as clozapine, were developed that
have a lower tendency for the induction of EPS. Atypical antipsychotics
are characterized by high-affinity ratio between serotonin 5-HT2 and
dopamine D2 receptors (Meltzer et al., 1989
). Their low propensity for
the induction of EPS is thought to depend on their ability to
preferentially inhibit mesolimbic dopaminergic system as opposed to
neuroleptic drugs that effectively inhibit both mesolimbic and
mesostriatal dopaminergic systems (Scatton and Sanger, 2000
).
The receptor binding profile of
9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline
bimaleinate (LEK-8829) was determined in vitro by displacement of
appropriate radioligands in preparations of rat brain membranes and of
cells expressing recombinant subtypes of human dopamine and serotonin
receptors. LEK-8829 is a nonselective compound that binds with high
affinity to dopamine D2 and D3 receptors and serotonin 5-HT1A, -2A, -6, and -7 receptors. It also has moderate to low affinity for serotonin 5-HT2C, dopamine D1, D5, and D4 receptors,
1- and
2-adrenergic receptors and sigma receptors. The
pKi ratio 5HT2A/D2 of LEK-8829 is
1.11, that is closer to the pKi ratio
5HT2A/D2 of atypical antipsychotic clozapine than to the
pKi ratio 5HT2A/D2 of typical antipsychotic haloperidol. According to Meltzer's classification, LEK-8829 was thus classified among atypical antipsychotics (Krisch et
al., 1996
).
At high concentrations (100 µM), LEK-8829 has stimulatory activity on
dopamine D1/D5 receptor-mediated cAMP accumulation in C6D1 cells.
LEK-8829 inhibited quinpirole-induced mitogenesis in CHOp-D2 and
CHOp-D3 cells (I. Krisch, personal communication). Agonistic activity of LEK-8829 on dopamine D1 receptors and
antagonistic activity on dopamine D2 receptors were demonstrated also
in vivo in rats with unilateral striatal lesions with ibotenic acid
(
prah et al., 1999
).
The potential of LEK-8829 for the induction of catalepsy and for the
blockade of behaviors induced by dopaminergic agonists has been
described as relatively low (Krisch et al., 1994
). This indicates that
LEK-8829 might have a low propensity for the induction of EPS.
Clozapine, a model atypical antipsychotic that is known for its low
propensity for extrapyramidal effects, also seems to have intrinsic
activity at dopamine D1 receptors (Ahlenius, 1999
). It may be
speculated, therefore, that the D1 agonistic activity could play a
pivotal role in regard to the effects of LEK-8829.
In rats that are rendered hemi-parkinsonian by unilateral lesions of
nigrostriatal neurons with 6-hydroxydopamine (6-OHDA model), D1
agonists trigger contralateral turning and augment the expression of
striatal neuropeptide mRNAs, such as preprotachykinin (PPT),
neurotensin (NT), and neurotransmitter-induced early gene protein 4 (ania-4), preferentially in dopamine-depleted striatum (Sonsalla et
al., 1988
; Gerfen et al., 1990
; Berke et al., 1998
; Hanson and Keefe,
1999
). By contrast, D2 antagonists block contralateral turning induced
by D2 agonists and augment the expression of NT and ania-4 mRNAs, only
within the intact striatum (Sonsalla et al., 1988
; Berke et al., 1998
;
Hanson and Keefe, 1999
).
In 6-OHDA model, LEK-8829 induced contralateral turning and
c-fos mRNA in dopamine depleted-striatum that could be
blocked by D1 antagonist SCH-23390, but not by D2 antagonist
haloperidol (
ivin et al., 1996
). These results
indicated D1 agonistic activity of LEK-8829. On the other hand, in
combination with SCH-23390, LEK-8829 antagonized the effects of D2
agonist bromocriptine, indicating D2 antagonistic activity of LEK-8829
(
ivin et al., 1998
).
We decided to monitor the effects of LEK-8829 on the expression of PPT,
NT, and ania-4 mRNAs in 6-OHDA model because these mRNAs are
differentially modulated by D1 agonists and D2 antagonists in
dopamine-intact and dopamine-depleted striatum. PPT mRNA is expressed
predominantly within striatonigral neurons (Gerfen et al., 1990
),
whereas NT and ania-4 mRNAs are probably expressed in striatonigral and
in striatopallidal neurons (Berke et al., 1998
; Hanson and Keefe,
1999
). In the intact striatum of 6-OHDA animals, D2 receptor-bearing
striatopallidal and D1 receptor-bearing striatonigral output pathways
are inhibited and stimulated by dopamine, respectively. On the lesioned
side, because of the lack of endogenous dopamine, the striatopallidal
pathway is maximally facilitated and striatonigral pathway is maximally
inhibited (Obeso et al., 2000
). In the present study, we therefore
hypothesized that LEK-8829 could differentially modulate the motor
outflow and striatal expression of NT, PPT, and ania-4 mRNAs on the
intact and dopamine-depleted side. To evaluate which effects of
LEK-8829 could be attributed to the blockade of dopamine D2 and which
to the stimulation of dopamine D1 receptors, we pretreated groups of
LEK-8829-treated animals by D1 antagonist SCH-23390 and/or by D2/D3
agonist quinpirole.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. We used 62 female Wistar rats. The animals were maintained on a 12-h light/dark cycle (lights on, 7:00 AM to 7:00 PM) in a temperature-controlled colony room at 22 to 24°C with free access to rodent pellets and tap water. Groups of four animals were housed in standard plastic cages with sawdust cover on the floor throughout the experiment. They were handled according to the NIH Guide for the Care and Use of Laboratory Animals.
Drugs.
The following drugs were used: apomorphine
hydrochloride (Sigma, St. Louis, MO) and
trans-(
)-4aR-4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo[3,4-g]-quinoline hydrochloride (quinpirole hydrochloride; Sigma/RBI, Natick, MA) were
dissolved in 0.9% saline containing 0.02% ascorbic acid; LEK-8829
(LEK, Ljubljana, Slovenia) was dissolved in 0.9% saline; R(+)7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH-23390; RBI) was dissolved in dimethyl sulfoxide; the
final solution was made up with 0.9% saline and dimethyl sulfoxide (2:1). The doses given refer to the form indicated above, except for
LEK-8829, which was calculated as the base. The drugs were administered
in a volume of 2 ml/kg s.c., except for quinpirole, which was injected
i.p.
6-Hydroxydopamine Lesions of the Nigrostriatal Pathway.
The
stereotaxic lesions were performed on experimentally naive female rats,
weighing between 150 and 200 g. The animals were anesthetized with
an i.p. injection of 2% xylazine hydrochloride (8 mg/kg; Rompun;
Bayer, Leverkusen, Germany), ketamine hydrochloride (60 mg/kg;
Ketanest; Parke Davis, Wien, Austria), atropine (0.6 mg/kg; Belupo,
Koprivnica, Croatia) and placed in a stereotaxic frame (TrentWells,
South Gate, CA). 6-Hydroxydopamine hydrobromide (8 µg of free base
dissolved in 0.9% saline containing 0.02% ascorbic acid; RBI) was
infused at a rate of 1 µl/min over 4 min into the right medial
forebrain bundle at the following coordinates: anterior, 3 mm; lateral,
1.2 mm; and ventral, 7.3 mm; from lambda, midline, and the surface of
the dura, respectively (stereotaxic coordinates; Paxinos and Watson,
1998
). The incisor bar was set 2.3 mm below the interaural line. The
infusion was delivered via 30-gauge stainless steel cannula connected
by polyethylene tubing to a 10-µl Hamilton syringe mounted on a
microdrive pump (Harvard Apparatus, South Natick, MA). At each
injection site, the cannula was left in place for 2 min before
retraction. After surgery, the lesioned animals were left for 4 weeks
to recover and to allow for neuronal degeneration.
Recording of Turning Behavior.
Each rat was placed in a
plastic cylindrical chamber (40-cm diameter) of the Lablinc automated
rotometer system (Colbourn Instruments, Allentown, PA) designed for the
electromechanical recording (Ungerstedt and Arbuthnott, 1970
) of
turning behavior of eight animals simultaneously. The data files of the
turning profiles of each animal (i.e., the full left/right turns per
minute) recorded by the L2T2S data acquisition software (Colbourn
Instruments) were graphically represented and analyzed using standard
Lotus 1-2-3 spreadsheet (Lotus Software, Cambridge, MA), running on a PC.
Apomorphine Test. To determine the development of nigrostriatal degeneration and to stabilize the turning response, the 6-hydroxydopamine-lesioned animals were primed to the stimulation of dopamine D1 and D2 receptors by the treatment with apomorphine hydrochloride (0.05 mg/kg) in the fourth postoperative week. The apomorphine-primed 6-hydroxydopamine-lesioned rats responding with at least 100 contralateral turns during apomorphine test were then randomly divided in experimental groups of four animals for experiments with drugs. The experiments with drugs started 1 week after the priming session with apomorphine.
Drug Treatment. Eight groups of apomorphine-primed 6-hydroxydopamine-lesioned rats were used. Each group was treated in two experimental sessions, with 1 week of drug-free period between the sessions. In the first experimental session all rats received LEK-8829 (1.7 mg/kg). In the second experimental session, groups received two injections given at 0 min and one injection at 20 min as follows: group 1, Sal/Sal+Sal (n = 7) received three injections of saline; group 2, Sal/Sal+LEK (n = 7) was injected with two injections of saline and LEK-8829 (1.7 mg/kg); group 3, SCH/Sal+LEK (n = 7) was injected with SCH-23390 (1 mg/kg), saline, and LEK-8829 (1.7 mg/kg); group 4, SCH/Sal+Sal (n = 7) was injected with SCH-23390 (1 mg/kg) and two injections of saline; group 5, Sal/Q +LEK (n = 7) was injected with quinpirole (0.25 mg/kg), saline and LEK-8829 (1.7 mg/kg); group 6, Sal/Q+Sal (n = 8) was injected with quinpirole (0.25 mg/kg) and two injections of saline; group 7, SCH/Q+LEK (n = 7) received SCH-23390 (1 mg/kg), quinpirole (0.25 mg/kg), and LEK-8829 (1.7 mg/kg); group 8, SCH/Q+Sal (n = 7) received SCH-23390 (1 mg/kg), quinpirole (0.25 mg/kg), and saline. In addition, two groups of four apomorphine-primed nonlesioned rats were treated in parallel by the same protocols as described for group 1 and group 2. All the animals were killed by decapitation 4 h after the last treatment injection.
Preparation, Fixation, and Storage of Brain Sections.
Brains
were rapidly removed and quickly frozen on dry ice and stored at
80°C until cryostat sections were cut. Coronal sections (10 µm)
were cut through the caudate-putamen and ventral midbrain, then thaw
mounted onto glass slides [previously coated with 0.01% solution of
poly(L-lysine) in diethyl pyrocarbonate
H2O]. The sections were fixed in 4%
phosphate-buffered paraformaldehyde for 5 min, washed in
phosphate-buffered saline (3 changes of 1 min each), dehydrated in 70%
ethanol for 5 min and stored in 95% ethanol at +4°C until processed
for in situ hybridization histochemistry.
Oligonucleotide Probes.
We used oligodeoxyribonucleotide
`antisense' probes (45 bases long) complementary to the rat tyrosine
hydroxylase (TH) mRNA (bases encoding 471-515, sequence 5'-AAC CAA ACC
AGG GCA CAC AGG GAG AAC CAT GCT GGA CTT CCT AAG-3'), to the rat
activity and neurotransmitter-induced early gene protein 4 (ania-4)
mRNA (bases encoding 4681-4725, sequence 5'-GGT ACA GCA TTT TCG AGG
AGA CTA CAG CAG AGA GGC ATG GAA GCT-3'), to the rat
neurotensin/neuromedin N (NT) mRNA (bases encoding 488-532 of exon 4, sequence 5'-GGG TTA ATT GTG TGT GCT CAA TTT TGT TAT AAT CTC TTA TAA
TTT-3'), and to the rat mRNA of
-PPT, a splicing variant of
substance P precursor (bases encoding 131-175, sequence 5'-TCG GGC GAT
TCT CTG AAG AAG ATG CTC AAA GGG CTC CGG CAT TGC-3'). GenBank accession
numbers used to designate the probes were as follows: TH, M23598;
ania-4, AF030089; NT, M21187; and PPT, X56306.
In Situ Hybridization Histochemistry.
The standard procedure
described in detail by Sirinathsinghji et al. (1990)
was performed.
Briefly, the sections were removed from ethanol, allowed to dry in the
air, and incubated with 35S-labeled probe in
hybridization buffer. The hybridization buffer contained 4× SSC (1×
SSC contains 150 mM sodium chloride and 15 mM sodium citrate), 50%
deionized formamide, 50 mM sodium phosphate, pH 7.0, 5× Denhardt's
solution, 100 µg/ml polyadenylic acid, 10% dextran sulfate, and 40 mM dithiothreitol. The oligodeoxynucleotide probes were labeled at the
3' end with [35S] dATP (1000-1500 Ci/mmol;
PerkinElmer Life Sciences, Boston, MA) and terminal
deoxynucleotidyl transferase enzyme (Roche Molecular Biochemcials, Mannheim, Germany) in a tailing buffer containing 500 mM
K+ cacodylate, 5 mM CoCl2
and 10 µM dithiothreitol. The incubation was performed in 1-ml
Eppendorf tubes for 1 h in a water bath at 35°C. After the
incubation, the labeled probes were purified by a spin column procedure
with Sephadex G50. The specific activities of the labeled probes were
determined by scintillation counting and ranged from 55 to 150 × 103 dpm/µl. Hybridization buffer (100 µl)
with labeled probe was applied to each slide, covered with a strip of
parafilm and incubated over night (approximately 16 h) at 42°C
in a humid chamber to prevent desiccation. For each probe, a few
control striatal sections were hybridized in the presence of 100-fold
excess of unlabeled probe. The washing was performed for 30 min at room
temperature followed by 1-h wash at 55°C in 1× SSC. The sections
were then dipped in 0.1× SSC for a few seconds, quickly dehydrated
through 50, 70, and 98% ethanol series, dried with a stream of cold
air and exposed to X-ray film (Hyperfilm
-max; Amersham Biosciences, Uppsala, Sweden). The autoradiograms were exposed at room temperature for 2 to 3 weeks and developed using standard darkroom techniques.
Image Analysis.
The semiquantitative densitometry of
hybridization signals of striatal NT, PPT, and ania-4 mRNAs was
performed by using MCID, M4 image analyzer (Imaging Research Inc.,
Canada). The relative optical density (ROD) of hybridization signal of
individual mRNAs was determined on dopamine-intact and -depleted sides
for each animal by manual outlining (with the help of stereotaxic
atlas) of the dorsal striatal region (region of interest; ROI). The
measurements were taken only for animals with no detectable TH and NT
mRNA signals at the ventral midbrain level on the 6-OHDA-lesioned
side. The lower limit of ROD threshold was visually adjusted to the level that eliminated pixels pertaining to corpus callosum (the region
with presumably no hybridization signal). The first parameter measured
was the ROD of the area covered by the above-threshold pixels within
ROI (RODROI). Background ROD (i.e.,
RODbckg of corpus callosum on the same section)
was measured separately and was subtracted from each
RODROI value. The second parameter measured was
the number of the above-threshold pixels within ROI (Total target area;
A). The total target area covered by PPT or ania-4 mRNA hybridization
signals corresponded to the anatomical outline of dorsal striatum. The
total target area of the above-threshold NT mRNA hybridization signal,
however, was smaller than the anatomical outline of striatum and varied
depending on the treatments, probably because different numbers of
striatal neurons were recruited by different treatments. We therefore
determined the integrated relative optical density iROD for the NT mRNA
hybridization signal (iROD = (RODROI
RODbckg) × A). For each animal, the average
intensity of the individual mRNA hybridization signals was finally
calculated from measurements performed on three striatal sections.
Statistical Analysis. For each treatment group, the intensity of contralateral turning and of striatal autoradiographic signals was expressed as means ± S.E.M. (n), where n represents the number of animals per treatment group. Statistical significance of the effects of treatments between treatment groups was evaluated by using one-way analysis of variance (ANOVA) followed by Scheffé's Multiple-Comparison Test. An unpaired Student's t test was performed to determine the statistical significance of the differences of the intensity of autoradiographic signals in denervated striatum of saline treated 6-OHDA rats in comparison with the intensity of autoradiographic signals in the striatum of saline treated, nonlesioned rats.
| |
Results |
|---|
|
|
|---|
Effect of LEK-8829 on Turning Behavior.
After a short latency
period of a few minutes, the first treatment with LEK-8829 (1.7 mg/kg)
induced intensive, long-lasting contralateral turning behavior of
apomorphine-primed 6-OHDA animals (n = 7; total number
of turns in first 4 h, 1542 ± 114; maximal frequency of
turning, 24 ± 2 turns/min). When the same group of animals
received LEK-8829 (1.7 mg/kg) again after a 1-week drug-free interval,
the animals displayed a rapid onset of even more vigorous contralateral
turning (n = 7; total number of turns in first 4 h, 2402 ± 215; p < 0.01, two-tailed Student's
t test; maximal frequency of turning, 26 ± 2 turns/min; Fig. 1A, group Sal/Sal+LEK). Contralateral turning was occasionally interrupted by periods of
stereotyped behavior characterized by contralateral twisting, compulsive licking, or scratching of the contralateral fore paw with
the teeth and/or in the region close to the hind leg. The interfering behavior apparently reduced the mean rotational speed and
the total number of turns performed by the animals. Pretreatment with
selective antagonist of dopamine D1 receptors, SCH-23390 (1 mg/kg),
which did not induce turning (Fig. 2,
group SCH/Sal+Sal), almost completely prevented the induction of
turning by LEK-8829 (Figs. 1B and 2, group SCH/Sal+LEK). Treatment with
selective agonist of dopamine D2 receptors quinpirole (0.25 mg/kg) that induced a rapid onset of intensive contralateral turning (Figs. 1D and
2, group Sal/Q+Sal) was significantly intensified by the coadministration of SCH-23390 (Figs. 1E and 2, group SCH/Q+Sal). The
pretreatment with quinpirole did not significantly affect the
LEK-8829-induced turning (Figs. 1F and 2, group Sal/Q+LEK). The
administration of LEK-8829, however, abruptly blocked the contralateral
turning induced by the combined treatment with quinpirole and SCH-23390
(Figs. 1C and 2, group SCH/Q+LEK).
|
|
Effect of Unilateral 6-Hydroxydopamine Lesions on Striatal mRNA
Expression.
In situ hybridization histochemistry of TH mRNA was
performed to select the animals showing a complete degeneration of
dopaminergic neurons. Only the animals with a complete loss of TH mRNA
signal at the film-autoradiographic level in substantia nigra
compacta/ventral tegmental area were selected for the
effects-of-treatment study on striatal gene expression. The nearly
total degeneration of nigrostriatal neurons resulted in a significant
increase of NT mRNA signals and a decrease in PPT mRNA signal in the
striatum ipsilateral to the lesioned side (Fig.
3). The 6-OHDA lesions did not affect the
striatal ania-4 mRNA signal (Fig. 3).
|
Effect of LEK-8829 on Striatal mRNA Expression.
In
dopaminergically deafferentated striatum, LEK-8829 (1.7 mg/kg)
significantly increased the intensity of NT, PPT, and ania-4 mRNA
autoradiographic signals (group Sal/Sal+LEK; Fig.
4). In dopaminergically intact striatum
of LEK-8829-treated 6-OHDA animals, we observed significant increase
of NT and ania-4 mRNA signals. PPT mRNA signal, however, was decreased
in dopamine-intact striatum of animals after the injection of LEK-8829
(group Sal/Sal+LEK; Fig. 4).
|
Effect of SCH-23390 on LEK-8829-Induced Striatal Gene Expression. In deafferentated striatum, the pretreatment with SCH-23390 (1 mg/kg) completely prevented LEK-8829-mediated changes of PPT, ania-4, and NT mRNA hybridization signals (group SCH/Sal+LEK; Fig. 4). In dopaminergically intact striatum, SCH-23390 only partially inhibited the LEK-8829-induced increase of NT mRNA signal and reversed LEK-8829-mediated decrease of PPT mRNA signal (group SCH/Sal+LEK, Fig. 4). SCH-23390 did not affect LEK-8829-induced increase of ania-4 mRNA hybridization signal.
Effect of Quinpirole on LEK-8829-Induced Striatal Gene Expression. In the deafferented striatum, pretreatment with quinpirole (0.25 mg/kg) increased LEK-8829-elevated PPT mRNA signal, but did not affect hybridization signals of other monitored mRNAs (group Sal+Q/LEK; Fig. 4). In the innervated striatum, pretreatment with quinpirole did not change LEK-8829-mediated effects on the intensity of NT and ania-4 mRNA signals, but prevented LEK-8829-mediated decrease of PPT mRNA signal (group Sal+Q/LEK; Fig. 4).
Effect of Combined Treatment with SCH-23390 and Quinpirole on LEK-8829-Induced Striatal Gene Expression. In the deafferented striatum, pretreatment with SCH-23390 (1 mg/kg) and quinpirole (0.25 mg/kg) inhibited LEK-8829-mediated increase of NT, PPT, and ania-4 mRNA signals (group SCH+Q/LEK; Fig. 4). In the innervated striatum, the combined pretreatment with SCH-23390 and quinpirole synergistically inhibited LEK-8829-induced changes of NT and ania-4 mRNA signals (group SCH+Q/LEK; Fig. 4).
Effect of Treatments with SCH-23390 and/or Quinpirole on Striatal
Gene Expression.
In the deafferented striatum, neither quinpirole
nor SCH-23390 given alone or in combination had any measurable effect
on NT or ania-4 mRNA signals, whereas the treatment with quinpirole (0.25 mg/kg) increased PPT mRNA signal (group Sal+Q/Sal; Fig. 5). In innervated striatum, the
treatments with quinpirole and/or SCH-23390 did not have any effect on
the monitored mRNA signals (Fig. 5).
|
Effect of LEK-8829 on Regional Distribution of NT mRNA.
In
saline treated, nonlesioned rats, LEK-8829 (1.7 mg/kg) induced NT mRNA
in dorsal striatum, shell, and core of nucleus accumbens, dorsal and
ventral parts of lateral septal nuclei, and within olfactory tubercle
(Fig. 6, D, E and F). The induction of NT
mRNA was more profound in rostral parts of neostriatum and nucleus accumbens than in caudal striatal regions (Fig. 6D).
|
| |
Discussion |
|---|
|
|
|---|
Effects of LEK-8829 on Turning Behavior. All 6-OHDA animals used in this study turned contralaterally after the treatment with low dose of mixed dopamine receptor agonist apomorphine. LEK-8829 induced vigorous, long-lasting contralateral turning in all apomorphine-primed 6-OHDA animals. When the same group of rats received LEK-8829 for the second time after 1 week of drug-free period, the turning became even more vigorous, indicating the development of dopaminergic sensitization.
In 6-OHDA model, contralateral turning could be induced by directly acting dopaminergic agonists that are selective for either pharmacological type of dopamine receptors and inhibited only by antagonists of the same dopamine receptor type that induced the turning (Sonsalla et al., 1988Effects of LEK-8829 on Striatal Gene Expression.
We
found a nearly complete absence of TH and NT mRNA hybridization signals
in substantia nigra compacta and in the ventral tegmental area on the
lesioned side. This is consistent with unilateral degeneration of
dopaminergic nigrostriatal, mesolimbic, and mesocortical neurons in our
experimental animals. In the striatum ipsilateral to the lesion, we
found increased abundance of striatal NT mRNA, decreased abundance of
striatal PPT mRNA, and unchanged abundance of striatal ania-4 mRNA.
These changes may be attributed to the striatal adaptations that
developed after nearly complete dopaminergic deafferentation (Sivam et
al., 1987
; Hanson and Keefe, 1999
).
| |
Acknowledgments |
|---|
We thank Dr. Igor Krisch and LEK Pharmaceutical Company for providing the unpublished data on binding affinities of LEK-8829 on cloned human dopamine D3 and D4 and serotonin 5-HT6 and 5-HT7 receptors.
| |
Footnotes |
|---|
Received April 30, 2001; Accepted November 8, 2001
This study was supported by grants from the Ministry of Science and Technology of Slovenia 381-518 and J3 8722, P3 521 381.
Dr. Marko 
ka 4, 1000 Ljubljana,
Slovenia. E-mail: zivin{at}mf.uni-lj.si
| |
Abbreviations |
|---|
EPS, extrapyramidal syndrome;
5-HT, 5-hydroxytryptamine;
LEK-8829, 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline
bimaleinate;
6-OHDA, 6-hydroxydopamine;
PPT, preprotachykinin;
NT, neurotensin;
ania-4, activity and neurotransmitter-induced early gene
protein 4;
quinpirole hydrochloride, trans-(
)-4aR-4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo[3,4-g]-quinoline
hydrochloride;
SCH-23390, R(+)7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
hydrochloride;
TH, tyrosine hydroxylase;
SSC, standard saline citrate;
ROD, relative optical density;
ROI, region of interest;
ANOVA, analysis
of variance.
| |
References |
|---|
|
|
|---|
prah L,
ivin M and
Sket D
(1999)
Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
J Pharmacol Exp Ther
288:
1093-1100
ivin M,
prah L and
Sket D
(1996)
The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions.
Br J Pharmacol
119:
1187-1196[Medline].
ivin M,
prah L and
Sket D
(1998)
Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine.
Eur J Pharmacol
349:
151-157[CrossRef][Medline].
This article has been cited by other articles:
![]() |
C. J. Schmidt, D. S. Chapin, J. Cianfrogna, M. L. Corman, M. Hajos, J. F. Harms, W. E. Hoffman, L. A. Lebel, S. A. McCarthy, F. R. Nelson, et al. Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 681 - 690. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||